Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference
https://doi.org/10.36485/1561-6274-2020-24-2-22-41
Abstract
The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline’s publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.
Supporting agencies: The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.
About the Authors
Jűrgen Floege
Rheinisch-Westfälische Technische Hochschule University of Aachen
Germany
Germany
Division of Nephrology and Clinical Immunology
Pauwelsstrasse 30, 52057 Aachen
Sean J. Barbour
British Columbia Provincial Renal Agency; University of British Columbia; St. Paul’s Hospital
Canada
Canada
Division of Nephrology, University of British Columbia
Centre for Health Evaluation and Outcomes Research, St. Paul’s Hospital
Vancouver, British Columbia
Daniel C. Cattran
University Health Network
Canada
Canada
Toronto General Research Institute
Toronto, Ontario
Jonathan J. Hogan
University of Pennsylvania
United States
United States
Division of Nephrology
Philadelphia, Pennsylvania
Patrick H. Nachman
University of Minnesota
United States
United States
Division of Renal Diseases and Hypertension
Minneapolis, Minnesota
Sydney C.W. Tang
The University of Hong Kong; Queen Mary Hospital
China
China
Department of Medicine, The University of Hong Kong
Hong Kong
Jack F.M. Wetzels
Radboud University Medical Center
Netherlands
Netherlands
Department of Nephrology
Nijmegen
Michael Cheung
KDIGO
Belgium
Brussels
Belgium
Brussels
David C. Wheeler
University College London
United Kingdom
London
United Kingdom
London
Wolfgang C. Winkelmayer
Baylor College of Medicine
United States
United States
Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine
Houston, Texas
Brad H. Rovin
The Ohio State University
United States
United States
Division of Nephrology, The Ohio State University, Wexner Medical Center
395 West 12th Avenue, Ground Floor, Columbus, Ohio 43210
References
1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:139–274. doi: 10.1038/kisup.2012.9
2. Sethi S, D’Agati VD, Nast CC et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int 2017;91:787–789. doi: 10.1016/j.kint.2017.01.002
3. D’Agati VD, Mengel M. The rise of renal pathology in nephrology: structure illuminates function. Am J Kidney Dis 2013;61:10161025. doi: 10.1053/j.ajkd.2012.12.019
4. Larsen CP, Messias NC, Silva FG et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013;26:709–715. doi: 10.1038/modpathol.2012.207
5. Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep 2015;5:8803. doi: 10.1038/srep08803
6. Hodgin JB, Bitzer M, Wickman L et al. Glomerular aging and focal global glomerulosclerosis: a podometric perspective. J Am Soc Nephrol 2015;26:3162–3178. doi: 10.1681/ASN.2014080752
7. Beck LH Jr, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543–1550. doi: 10.1681/ASN.2010111125
8. De Vriese AS, Glassock RJ, Nath KA et al. A proposal for a serologybased approach to membranous nephropathy. J Am Soc Nephrol 2017;28:421–430. doi: 10.1681/ASN.2016070776
9. Sethi S, Glassock RJ, Fervenza FC. Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 2015;30:375–384. doi: 10.1093/ndt/gfu035
10. Hogan MC, Reich HN, Nelson PJ et al. The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. Kidney Int 2016;90:1080–1089. doi: 10.1016/j.kint.2016.06.020
11. Reich HN, Troyanov S, Scholey JW et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18:3177–3183. doi: 10.1681/ASN.2007050526
12. Lv J, Zhang H, Wong MG et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318:432–442. doi: 10.1001/jama.2017.9362
13. Hebert LA, Birmingham DJ, Shidham G et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract 2009;113:c177–c182. doi: 10.1159/000232599
14. Rizk DV, Meier D, Sandoval RM et al. A novel method for rapid bedside measurement of GFR. J Am Soc Nephrol 2018;29:1609–1613. doi: 10.1681/ASN.2018020160
15. Ix JH, Wassel CL, Stevens LA et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol 2011;6:184–191. doi: 10.2215/CJN.05030610
16. Gao A, Cachat F, Faouzi M et al. Comparison of the glomerular filtration rate in children by the new revised Schwartz formula and a new generalized formula. Kidney Int 2013;83:524–530
17. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009;4: 1832–1843. doi: 10.2215/CJN.01640309
18. Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005;20:707–711. doi: 10.1093/ndt/gfh719
19. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20:2305–2313. doi: 10.1681/ASN.2009020171
20. Inker LA, Tonelli M, Hemmelgarn BR, et al. Comparison of concurrent complications of CKD by 2 risk categorization systems. Am J Kidney Dis 2012;59:372–381. doi: 10.1053/j. ajkd.2011.09.021
21. Tang LL, Liu A, Chen Z et al. Nonparametric ROC summary statistics for correlated diagnostic marker data. Stat Med 2013; 32:2209–2220. doi: 10.1002/sim.5654
22. Geetha D, Seo P, Ellis C et al. Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy. J Rheumatol 2012;39:1413–1417. doi: 10.3899/jrheum.111608
23. Sevillano AM, Gutierrez E, Yuste C et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol 2017;28: 3089–3099. doi: 10.1681/ASN.2017010108
24. Levey AS, Inker LA, Matsushita K et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014;64:821–835. doi: 10.1053/j.ajkd.2014.07.030
25. Thompson A, Cattran DC, Blank M et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 2015;26:2930–2937. doi: 10.1681/ASN.2015010091
26. Cattran DC, Kim ED, Reich H et al. Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol 2017;28: 995–1003. doi: 10.1681/ASN.2015111262
27. Morrell GR, Zhang JL, Lee VS. Magnetic resonance imaging of the fibrotic kidney. J Am Soc Nephrol 2017;28:2564–2570. doi: 10.1681/ASN.2016101089
28. Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: one or many therapies? Kidney Int 2001;59:1211–1226. doi: 10.1046/j.1523-1755.2001.0590041211.x
29. Bertram JF, Douglas-Denton RN, Diouf B et al. Human nephron number: implications for health and disease. Pediatr Nephrol 2011;26:1529–1533. doi: 10.1007/s00467-011-1843-8
30. Ricardo AC, Goh V, Chen J et al. Association of sleep duration, symptoms, and disorders with mortality in adults with chronic kidney disease. Kidney Int Rep 2017;2:866–873. doi: 10.1016/j.ekir.2017.05.002
31. Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319–327. doi: 10.1053/ajkd.2003.50039
32. Afshinnia F, Wilt TJ, Duval S et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010;25:1173–1183. doi: 10.1093/ndt/gfp640
33. Kittiskulnam P, Kanjanabuch T, Tangmanjitjaroen K et al. The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial. J Ren Nutr 2014;24:200–207. doi: 10.1053/j.jrn.2014.01.016
34. Cattran DC, Reich HN, Beanlands HJ et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008;23: 2247–2253. doi: 10.1093/ndt/gfm919
35. Sampson MG, Hodgin JB, Kretzler M. Defining nephrotic syndrome from an integrative genomics perspective. Pediatr Nephrol 2015;30:51–63
36. Preston R, Stuart HM, Lennon R. Genetic testing in steroidresistant nephrotic syndrome: why, who, when and how? Pediatr Nephrol 2019;34(2):195–210. doi: 10.1007/s00467-017-3838-6
37. Agarwal R. Resistant hypertension and the neglected antihypertensive: sodium restriction. Nephrol Dial Transplant 2012;27:4041–4045. doi: 10.1093/ndt/gfs384
38. Bibbins-Domingo K, Chertow GM, Coxson PG et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010;362:590–599. doi: 10.1056/NEJMoa0907355
39. Voskamp PWM, Dekker FW, van Diepen M et al. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study. J Am Soc Hypertens 2017;11:635–643. doi: 10.1016/j.jash.2017.07.006
40. Joseph JJ, Echouffo-Tcheugui JB, Kalyani RR et al. Aldosterone, renin, cardiovascular events, and all-cause mortality among African Americans: the Jackson Heart Study. JACC Heart Fail 2017;5:642–651. doi: 10.1016/j.jchf.2017.05.012
41. Petrykiv SI, Laverman GD, Persson F et al. Pooled analysis of multiple crossover trials to optimize individual therapy response to rennin-angiotensin-aldosterone system intervention. Clin J Am Soc Nephrol 2017;12:1804–1813. doi: 10.2215/CJN.00390117
42. Antlanger M, Bernhofer S, Kovarik JJ et al. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in nondiabetic chronic kidney disease. Ann Med 2017;49:525–533. doi: 10.1080/07853890.2017.1313447
43. Rajasekeran H, Reich HN, Hladunewich MA et al. Dapagliflozin in focal segmental glomerulosclerosis: a combined humanrodent pilot study. Am J Physiol Renal Physiol 2018;314:F412–F422. doi: 10.1152/ajprenal.00445.2017
44. Markossian T, Burge N, Ling B et al. Controversies regarding lipid management and statin use for cardiovascular risk reduction in patients with CKD. Am J Kidney Dis 2016;67:965–977. doi: 10.1053/j.ajkd.2015.12.030
45. Lee T, Derebail VK, Kshirsagar AV et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int 2016;89:1111–1118. doi: 10.1016/j.kint.2015.12.041
46. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664
47. Kotur-Stevuljevic J, Peco-Antic A, Spasic S et al. Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephrol 2013;28:295–303. doi: 10.1007/s00467-012-2323-5
48. Haynes R, Lewis D, Emberson J et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014;25:1825–1833. doi: 10.1681/ASN.2013090965
49. Lee T, Biddle AK, Lionaki S et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int 2014;85:1412–1420. doi: 10.1038/ki.2013.476
50. Barbour SJ, Greenwald A, Djurdjev O et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012;81:190–195. doi: 10.1038/ki.2011.312
51. Stamellou E, Floege J. Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. Nephrol Dial Transplant 2018;33:1683–1689. doi: 10.1093/ndt/gfx322
52. Cholongitas E, Haidich AB, Apostolidou-Kiouti F et al. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol 2018;31:480–490. doi: 10.20524/aog.2018.0266
53. National Renal Complement Therapeutics Centre. Guidelines for the prevention of meningococcal disease in adult patients receiving eculizumab for the treatment of atypical haemolytic uraemic syndrome. Available at: http://www.atypicalhus.co.uk/wp-content/uploads/2017/07/Meningococcal-guidelines-adult1.pdf. Accessed April 17, 2018
54. Perkovic V, Agarwal R, Fioretto P et al. Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016;90:1175–1183. doi: 10.1016/j.kint.2016.09.010
55. Ayme S, Bockenhauer D, Day S et al. Common elements in rare kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017;92:796–808. doi: 10.1016/j.kint.2017.06.018
56. Gadegbeku CA, Gipson DS, Holzman LB et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013;83:749–756. doi: 10.1038/ki.2012.428
57. Ju W, Nair V, Smith S et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 2015;7:316ra193. doi: 10.1126/scitranslmed.aac7071
58. Boyd JK, Cheung CK, Molyneux K et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012;81:833–843. doi: 10.1038/ki.2011.501
59. Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 2018;33:763–777. doi: 10.1007/s00467-017-3699-z
60. Berthoux F, Suzuki H, Thibaudin L et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;23:1579–1587. doi: 10.1681/ASN.2012010053
61. Yasutake J, Suzuki Y, Suzuki H et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 2015;30:1315-1321. doi: 10.1093/ndt/gfv221
62. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321–327. doi: 10.1038/ng.787
63. Fellstrom BC, Barratt J, Cook H et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a doubleblind, randomised, placebo-controlled phase 2b trial. Lancet 2017;389:2117–2127. doi: 10.1016/S01406736(17)30550-0
64. Suzuki H, Suzuki Y, Narita I et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008;19:23842395. doi: 10.1681/ASN.2007121311
65. Niu D, Gao Y, Xie L et al. Genetic polymorphisms in TNFSF13 and FDX1 are associated with IgA nephropathy in the Han Chinese population. Hum Immunol 2015;76:831–835. doi: 10.1016/j.humimm.2015.09.044
66. McCarthy DD, Kujawa J, Wilson C et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 2011;121:3991–4002. doi: 10.1172/JCI45563
67. Maillard N, Wyatt RJ, Julian BA et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 2015;26:1503–1512. doi: 10.1681/ASN.2014101000
68. Xie J, Kiryluk K, Li Y et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol 2016;27:3187–3194. doi: 10.1681/ASN.2015111210
69. Rosenblad T, Rebetz J, Johansson M et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014;29: 2225–2228. doi: 10.1007/s00467-014-2863-y
70. Ring T, Pedersen BB, Salkus G et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015;8:489–491. doi: 10.1093/ckj/sfv076
71. Block GA, Whitaker S. Maintenance of remission following completion of OMS721 treatment in patients with IgA nephropathy (IGAN). Abstract SA-PO278. J Am Soc Nephrol 2017;28:749–750
72. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534–545. doi: 10.1038/ki.2009.243
73. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009;76:546–556. doi: 10.1038/ki.2009.168
74. Coppo R, Troyanov S, Bellur S et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014;86:828–836. doi: 10.1038/ki.2014.63
75. Barbour SJ, Espino-Hernandez G, Reich HN et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 2016;89:167–175. doi: 10.1038/ki.2015.322
76. Haas M, Verhave JC, Liu ZH et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 2017;28:691–701. doi: 10.1681/ASN.2016040433
77. Tesar V, Troyanov S, Bellur S et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 2015;26:2248–2258. doi: 10.1681/ASN.2014070697
78. Herzenberg AM, Fogo AB, Reich HN et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 2011;80:310–317. doi: 10.1038/ki.2011.126
79. Espinosa M, Ortega R, Sanchez M et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2014;9:897–904. doi: 10.2215/CJN.09710913
80. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD; Bethesda, MD: US Food and Drug Administration; National Institutes of Health; 2016. Available at: https://www.ncbi.nlm.nih.gov/books/NBK326791/. Accessed May 1, 2018
81. Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463
82. Rauen T, Fitzner C, Eitner F et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol 2018;29:317–325. doi: 10.1681/ASN.2017060713
83. Sarcina C, Tinelli C, Ferrario F et al. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 2016;11:973–981. doi: 10.2215/CJN.02300215
84. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebocontrolled randomized study. Kidney Int 2004;65:1842–1849. doi: 10.1111/j.1523-1755.2004.00588.x
85. Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139–2145. doi: 10.1093/ndt/gfh974
86. Hogg RJ, Bay RC, Jennette JC et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 2015;66:783–791. doi: 10.1053/j.ajkd.2015.06.013
87. Hou JH, Le WB, Chen N et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 2017;69:788–795. doi: 10.1053/j.ajkd.2016.11.027
88. Kawamura T, Yoshimura M, Miyazaki Y et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014;29:1546–1553. doi: 10.1093/ndt/gfu020
89. Feehally J, Coppo R, Troyanov S et al. Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy. Nephron 2016;132:15–24. doi: 10.1159/000441852
90. Barbour SJ, Cattran DC, Kim SJ et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to endstage renal disease. Kidney Int 2013;84:1017–1024. doi: 10.1038/ki.2013.210
91. Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001;110:434–437. doi: 10.1016/s0002-9343(01)00659-3
92. Gutierrez E, Zamora I, Ballarin JA et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012;23:1753–1760. doi: 10.1681/ASN.2012010063
93. Tang SC, Tang AW, Wong SS et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543–549. doi: 10.1038/ki.2009.499
94. Lafayette RA, Canetta PA, Rovin BH et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 2017;28:1306–1313. doi: 10.1681/ASN.2016060640
95. Yu MY, Kim YC, Chin HJ. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of glomerular filtration rate during 5 yearfollow up period in IgA nephropathy. Abstract SA-PO272. J Am Soc Nephrol 2017;28:748
96. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11–21. doi: 10.1056/NEJMoa0810457
97. Tomas NM, Beck LH Jr, Meyer-Schwesinger C et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371:2277–2287. doi: 10.1056/NEJMoa1409354
98. Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLADQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364:616–626. doi: 10.1056/NEJMoa1009742
99. Cui Z, Xie LJ, Chen FJ et al. MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy. J Am Soc Nephrol 2017;28:1651–1664. doi: 10.1681/ASN.2016020114
100. Du Y, Li J, He F et al. The diagnosis accuracy of PLA2RAB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS One 2014;9:e104936. doi: 10.1371/journal.pone.0104936
101. Dahan K, Debiec H, Plaisier E et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 2017;28:348–358. doi: 10.1681/ASN.2016040449
102. Hofstra JM, Wetzels JF. Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. J Am Soc Nephrol 2014;25:1137–1139. doi: 10.1681/ASN.2014010091
103. Seitz-Polski B, Debiec H, Rousseau A et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J Am Soc Nephrol 2018;29:401–408. doi: 10.1681/ASN.2017070734
104. Radice A, Trezzi B, Maggiore U et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 2016;15:146–154. doi: 10.1016/j.autrev.2015.10.004
105. Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 2013;9:443–458. doi: 10.1038/nrneph.2013.125
106. van de Logt AE, Hofstra JM, Wetzels JF. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol 2016;9:1463–1478. doi: 10.1080/17512433.2016.1225497
107. Ramachandran R, Hn HK, Kumar V et al. Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology 2016;21:139–146. doi: 10.1111/nep.12569
108. Qiu TT, Zhang C, Zhao HW et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials. Autoim-mun Rev 2017;16:136–145. doi: 10.1016/j.autrev.2016.12.005
109. Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013;381:744–751. doi: 10.1016/S0140-6736(12)61566-9
110. van den Brand J, Ruggenenti P, Chianca A et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 2017;28:2729–2737. doi: 10.1681/ASN.2016091022
111. Ruggenenti P, Debiec H, Ruggiero B et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 2015;26:2545–2558. doi: 10.1681/ASN.2014070640
112. Hofstra JM, Debiec H, Short CD et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1735–1743. doi: 10.1681/ASN.2012030242
Review
For citations:
Floege J., Barbour S., Cattran D., Hogan J., Nachman P., Tang S., Wetzels J., Cheung M., Wheeler D., Winkelmayer W., Rovin B. Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Nephrology (Saint-Petersburg). 2020;24(2):22-41. (In Russ.) https://doi.org/10.36485/1561-6274-2020-24-2-22-41
Views:
2423
Email this article 